Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2024 | $12.00 | Buy | Rodman & Renshaw |
| 10/30/2024 | $12.00 | Buy | H.C. Wainwright |
| 9/24/2024 | $12.00 | Buy | Maxim Group |
Rodman & Renshaw initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00
H.C. Wainwright initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00
Maxim Group initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00
HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced it has closed the third $5 million tranche of the previously announced Standby Equity Purchase Agreement (the "SEPA") with YA II PN, Ltd. ("Yorkville"), an investment fund managed by Yorkville Advisors Global, LP. The agreement allows FibroBiologics, subject to customary conditions, to sell up to $25 million in the aggregate of its common stock to Yorkville over th
HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present a company update at the BIO International Convention 2025, June 16-19, 2025, in Boston, MA. The presentation will include recent corporate milestones and research advances using fibroblast-based technology for indications such as wound healing, multiple sclerosis, and psoriasis. "The BIO Interna
HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Jason D. Davis, CPA, as Chief Financial Officer, effective immediately. Mr. Davis brings extensive experience in corporate finance, capital markets, and SEC reporting, with a proven track record of successfully leading companies through critical growth phases, including IPOs and capital raising initiatives. His appointment comes as FibroBiologic
8-K - FibroBiologics, Inc. (0001958777) (Filer)
8-K - FibroBiologics, Inc. (0001958777) (Filer)
8-K - FibroBiologics, Inc. (0001958777) (Filer)